Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TYP007
MIFTS: 63

Typhoid Fever

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Typhoid Fever

About this section

MalaCards integrated aliases for Typhoid Fever:

Name: Typhoid Fever 12 52 58 54 3 43 15 17 71 32
Typhoid 12 74 52 58 15
Typhoidal Salmonellosis 58
Enteric Fever 52

Characteristics:

Orphanet epidemiological data:

58
typhoid
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),>1/1000 (South East Asia),1-5/10000 (Latin America),1-5/10000 (Africa),1-9/1000000 (North America),1-5/10000 (Oceania),1-9/1000000 (France); Age of onset: All ages; Age of death: adolescent,late childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare infectious diseases


Sources

Summaries for Typhoid Fever

About this section
Disease Ontology : 12 A primary bacterial infectious disease that is a communicable systemic illness, has material basis in Salmonella enterica subsp enterica serovar Typhi, which is transmitted by ingestion of food or water contaminated with the feces of an infected person. The infection has symptom fever, has symptom diarrhea, has symptom prostration, has symptom headache, has symptom splenomegaly, has symptom liver enlargement, has symptom eruption of rose-colored spots, and has symptom leukopenia.

MalaCards based summary : Typhoid Fever, also known as typhoid, is related to paratyphoid fever and salmonellosis, and has symptoms including splenomegaly, fever and headache. An important gene associated with Typhoid Fever is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Gatifloxacin and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are fatigue and fever

CDC : 3 Typhoid fever and paratyphoid fever are life-threatening illnesses caused by Salmonella serotype Typhi and Salmonella serotype Paratyphi, respectively. Most people in the United States with typhoid fever or paratyphoid fever become infected while traveling abroad, most often to countries where these diseases are common. If you plan to travel outside of the United States, find out if you need the typhoid fever vaccine at www.cdc.gov/travel.

Wikipedia : 74 Typhoid fever, also known simply as typhoid, is a bacterial infection due to a specific type of... more...

Sources

Related Diseases for Typhoid Fever

About this section

Diseases related to Typhoid Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1014)
# Related Disease Score Top Affiliating Genes
1 paratyphoid fever 32.9 TNF IL1B IL1A IFNGR1 IFNG CRP
2 salmonellosis 32.1 VDAC1 TNF TLR5 TLR4 SLC11A1 IL6
3 epidemic typhus 31.6 TLR5 TLR4 GPT CRP
4 cholecystitis 31.6 TLR4 GPT F2 ALB
5 intestinal perforation 31.5 TNF TLR4 IL6 GPT CRP ALB
6 cholera 31.4 TNF IL6 IL1B CFTR
7 myocarditis 31.4 TNF TLR4 IL6 IL1B IFNG
8 guillain-barre syndrome 31.3 TNF HLA-DRB1 ALB
9 acalculous cholecystitis 31.3 GPT F2 CRP ALB
10 acute kidney failure 31.3 GPT F2 ALB
11 diphtheria 31.2 TNF IL1B IFNG ALB
12 smallpox 31.2 TNF IL1B IFNG
13 splenic abscess 31.2 GPT F2 CRP ALB
14 disseminated intravascular coagulation 31.2 TNF IL6 GPT F2 CRP
15 constipation 31.2 TNF IL6 GPT CRP ALB
16 pancytopenia 31.1 IL6 IFNG CRP ALB
17 diarrhea 31.1 TNF TLR4 IL6 IL1B IFNG GPT
18 ascaris lumbricoides infection 31.1 IL6 IL1B IFNG
19 hepatitis a 31.1 TNF TLR4 IL1B IFNG GPT F2
20 pleural empyema 31.1 F2 CRP ALB
21 brucellosis 31.1 TNF TLR4 SLC11A1 IL6 IFNG CRP
22 neuritis 31.0 TNF IL6 IL1B IFNG
23 gastroenteritis 31.0 TNF IL6 IL1B IFNG CRP ALB
24 scarlet fever 31.0 TNF CRP ALB
25 spotted fever 31.0 TNF IFNG F2
26 deficiency anemia 31.0 TNF SLC11A1 IL6 CRP ALB
27 adult respiratory distress syndrome 31.0 TNF IL6 IL1B F2
28 hepatic coma 31.0 GPT F2 ALB
29 intussusception 30.9 IL6 CRP CFTR ALB
30 gastritis 30.9 TNF TLR4 IL6 IL1B
31 dysentery 30.9 TNF TLR4 IL6 IL1B IL1A GPT
32 toxic megacolon 30.9 TNF CRP ALB
33 pancreatitis 30.9 TNF IL6 IL1B CRP CFTR ALB
34 neutropenia 30.9 TNF TLR4 IL6 IL1B IFNG GPT
35 purpura 30.9 TNF IL6 IFNG F2 CRP
36 acute kidney tubular necrosis 30.9 TNF IL6 ALB
37 legionnaire disease 30.8 TLR5 TLR4 CRP CASP1
38 tularemia 30.8 TNF TLR4 SLC11A1 IL1B CASP1
39 yellow fever 30.8 LTA IL6 IL1B IL1A CRP
40 appendicitis 30.8 TNF TLR4 IL6 IL1B IFNG CRP
41 acute liver failure 30.8 GPT F2 ALB
42 ileitis 30.8 TNF TLR5 TLR4 IL6
43 bilirubin metabolic disorder 30.8 GPT F2 CRP ALB
44 orchitis 30.8 TNF IL6 IL1B CRP
45 optic neuritis 30.8 TNF LTA IL6 IL1B HLA-DRB1
46 peritonitis 30.8 TNF TLR4 IL6 IL1B IFNG F2
47 amebiasis 30.8 TNF TLR4 IL1B ALB
48 esophagitis 30.7 TNF IL6 IL1B
49 iritis 30.7 TNF IL6 CRP
50 shigellosis 30.7 TNF TLR5 TLR4 LTA IL1B CASP1

Graphical network of the top 20 diseases related to Typhoid Fever:



Diseases related to Typhoid Fever
Sources

Symptoms & Phenotypes for Typhoid Fever

About this section

Human phenotypes related to Typhoid Fever:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
4 insomnia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100785
5 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
6 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
7 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
8 hypertonia 58 31 frequent (33%) Frequent (79-30%) HP:0001276
9 ataxia 58 31 frequent (33%) Frequent (79-30%) HP:0001251
10 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
11 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
12 macule 58 31 frequent (33%) Frequent (79-30%) HP:0012733
13 hyperreflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001347
14 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
15 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
16 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
17 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
18 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
19 constipation 58 31 occasional (7.5%) Occasional (29-5%) HP:0002019
20 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
21 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
22 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
23 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
24 interstitial pulmonary abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0006530
25 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
26 cardiac arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0001695
27 arrhythmia 58 Frequent (79-30%)

Symptoms:

12
  • • splenomegaly
  • • fever
  • • headache
  • • diarrhea
  • • leukopenia
  • • prostration
  • • liver enlargement
  • • eruption of rose-colored spots

GenomeRNAi Phenotypes related to Typhoid Fever according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 IL1A IL1B LTA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CASP1 CFTR IL1B LTA TNF

MGI Mouse Phenotypes related to Typhoid Fever:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 ALB CASP1 CRP F2 IFNG IFNGR1
2 homeostasis/metabolism MP:0005376 10.34 ALB CASP1 CFTR CRP F2 IFNG
3 behavior/neurological MP:0005386 10.29 CFTR F2 IFNG IFNGR1 IL6 LTA
4 immune system MP:0005387 10.28 ALB CASP1 CFTR CRP F2 IFNG
5 hematopoietic system MP:0005397 10.27 CASP1 CFTR F2 IFNG IFNGR1 IL1A
6 digestive/alimentary MP:0005381 10.22 ALB CASP1 CFTR F2 IFNG IFNGR1
7 mortality/aging MP:0010768 10.16 ALB CASP1 CFTR F2 IFNG IFNGR1
8 integument MP:0010771 10.07 CASP1 F2 IFNG IFNGR1 IL1A IL1B
9 liver/biliary system MP:0005370 9.97 ALB CFTR IFNG IFNGR1 IL6 LTA
10 neoplasm MP:0002006 9.85 ALB CASP1 IFNG IFNGR1 IL1A IL1B
11 nervous system MP:0003631 9.73 CASP1 F2 IFNG IFNGR1 IL1B IL6
12 respiratory system MP:0005388 9.28 CFTR F2 IFNG IL6 LTA OMP
Sources

Drugs & Therapeutics for Typhoid Fever

About this section

Drugs for Typhoid Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
2
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
3
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
4
Azithromycin Approved Phase 4 83905-01-5 447043 55185
5
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
9 Ophthalmic Solutions Phase 4
10 Immunologic Factors Phase 4
11 Trace Elements Phase 4
12 Nutrients Phase 4
13 Micronutrients Phase 4
14 Vitamins Phase 4
15 Antioxidants Phase 4
16 Protective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
21
Sulfamethoxazole Approved Phase 3 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
23 Vaccines Phase 3
24 Antiparasitic Agents Phase 3
25 Antiprotozoal Agents Phase 3
26 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
27 Antimalarials Phase 3
28
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
29
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
30
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
31
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
32
Secnidazole Approved Phase 1, Phase 2 3366-95-8
33
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
34
Lumefantrine Approved Phase 2 82186-77-4 6437380
35
Artemether Approved Phase 2 71963-77-4 68911 9796294 119380
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
37 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
38 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
39 Retinol palmitate Phase 2
40 retinol Phase 2
41 Anthelmintics Phase 1, Phase 2
42 Tubulin Modulators Phase 1, Phase 2
43 Dermatologic Agents Phase 1, Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 diuretics Phase 2
46 Lecithin Phase 1, Phase 2
47 Soy Bean Phase 1, Phase 2
48 Pharmaceutical Solutions Phase 2
49 Immunoglobulins Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal. Unknown status NCT02224040 Phase 4 ceftriaxone;ceftriaxone and azithromycin;azithromycin;azithromycin and cefixime
2 Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae Unknown status NCT02121145 Phase 4
3 Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever. Completed NCT01421693 Phase 4 Ceftriaxone;Gatifloxacin
4 Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi, Guangxi, P.R. China: A Group-Randomized Controlled Demonstration Project Completed NCT00131833 Phase 4
5 Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students Completed NCT00131820 Phase 4
6 Randomized Controlled Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever in Eastern Kolkata, West Bengal, India Completed NCT00125008 Phase 4
7 Effectiveness of a Combined Vi Vaccination and Health Education Program on Reducing the Burden of Typhoid During Childhood: A Demonstration Project in Karachi Completed NCT00125047 Phase 4
8 Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy Recruiting NCT04154722 Phase 4 Meropenem Injection;Azithromycin Powder
9 CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults Recruiting NCT03970304 Phase 4 Vivotif Typhoid Oral Vaccine
10 CVD 38000: Immunity, Microbiome, Epigenetics, and a Systems Biology Approach to the Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
11 Collection of Blood Samples for In-Vitro Studies From Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A) Recruiting NCT03971669 Phase 4 Vivotif Typhoid Oral Vaccine
12 Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation Recruiting NCT03889158 Phase 4
13 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study) Active, not recruiting NCT02868970 Phase 4
14 Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Active, not recruiting NCT03312699 Phase 4
15 Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-patient Treatment of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia; a Randomised Controlled Trial Not yet recruiting NCT04349826 Phase 4 Azithromycin;Cefixime;Placebo
16 Multicenter, Randomized, Open-label Non-inferiority Trial, Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte) Not yet recruiting NCT04211649 Phase 4 3 days of antibiotherapy
17 Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects Completed NCT01608815 Phase 3
18 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
19 A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine Completed NCT00197249 Phase 3
20 Improving the Immune Response to Rotavirus Vaccine Completed NCT01825109 Phase 3
21 Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine) Recruiting NCT04051268 Phase 3
22 A Phase III Randomized, Double-Blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Recruiting NCT03299426 Phase 3
23 A Phase III, Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Immune Equivalence of Multi-dose Formulation Against Single-dose Formulation of Vi-DT Typhoid Conjugate Vaccine and Safety in Healthy Filipino...... Recruiting NCT04204096 Phase 3
24 Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal Active, not recruiting NCT02773407 Phase 3 Azithromycin;Co-trimoxazole
25 A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants. Active, not recruiting NCT03933098 Phase 3
26 A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningococcal ACWY), Using a Human Challenge Model of Typhoid Infection Unknown status NCT02324751 Phase 2
27 A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Completed NCT00498654 Phase 2
28 A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Completed NCT01229176 Phase 2
29 A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants Completed NCT01437267 Phase 2
30 A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age Completed NCT01193907 Phase 2
31 A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907) Completed NCT01438996 Phase 2
32 A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC‾ssaV‾) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA. Completed NCT00679172 Phase 2
33 A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, In-Patient Phase I/II Study to Determine the Safety and Immunogenicity of Ty800 in Healthy Adult Subjects Completed NCT00269295 Phase 1, Phase 2 Placebo
34 Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP Completed NCT00342628 Phase 2
35 Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II) Completed NCT03460405 Phase 2
36 A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Completed NCT03614533 Phase 2
37 Studies of Acute and Memory Immune Responses to Orally Administered Vaccines in Developing Country Children and Factors That May Augment Such Responses Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
38 MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study Completed NCT01911702 Phase 2
39 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient Completed NCT02338700 Phase 1, Phase 2
40 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Breast Carcinoma Patient Completed NCT02338804 Phase 1, Phase 2
41 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Hepatocyte Carcinoma Patient Completed NCT02338778 Phase 1, Phase 2
42 Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Pancreatic Carcinoma Patient Completed NCT02338752 Phase 1, Phase 2
43 Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control. Active, not recruiting NCT01405521 Phase 2
44 A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers Active, not recruiting NCT03527355 Phase 2
45 Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali Active, not recruiting NCT03917654 Phase 2
46 An Open-label Bi-centric Study of Local Immunomodulation Treatment Combined With Radiofrequency Ablation for Unresectable Colorectal Liver Metastases Not yet recruiting NCT04062721 Phase 1, Phase 2 Chemotherapy;In situ immunotherapy
47 A Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis. Terminated NCT00751933 Phase 2
48 A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age. Completed NCT01123941 Phase 1
49 Phase I Trial of a Live Oral Salmonella Enterica Serovar Paratyphi A Vaccine Harboring Mutations in guaBA and clpX Completed NCT01129453 Phase 1
50 An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Completed NCT03956524 Phase 1

Search NIH Clinical Center for Typhoid Fever

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin

Cochrane evidence based reviews: typhoid fever

Sources

Genetic Tests for Typhoid Fever

About this section
Sources

Anatomical Context for Typhoid Fever

About this section

MalaCards organs/tissues related to Typhoid Fever:

40
Testes, Liver, Colon, Bone, T Cells, Skin, Bone Marrow
Sources

Publications for Typhoid Fever

About this section

Articles related to Typhoid Fever:

(show top 50) (show all 11758)
# Title Authors PMID Year
1
Polymorphisms in proinflammatory genes and susceptibility to typhoid fever and paratyphoid fever. 54 61
17477815 2007
2
Rapid diagnosis of typhoid fever by enzyme-linked immunosorbent assay detection of Salmonella serotype typhi antigens in urine. 61 54
15031525 2004
3
A Salmonella protein causes macrophage cell death by inducing autophagy. 54 61
14662750 2003
4
Typhoid fever and genetic polymorphisms at the natural resistance-associated macrophage protein 1. 61 54
11237848 2001
5
Rapid serologic diagnosis of pediatric typhoid fever in an endemic area: a prospective comparative evaluation of two dot-enzyme immunoassays and the Widal test. 54 61
10548305 1999
6
Diagnosis of typhoid fever: detection of Salmonella typhi porins-specific antibodies by inhibition ELISA. 54 61
8222322 1993
7
Detection of antibodies against Salmonella typhi outer membrane protein (OMP) preparation in typhoid fever patients. 61 54
8216558 1993
8
Early diagnosis of typhoid fever by an enzyme immunoassay using Salmonella typhi outer membrane protein preparations. 54 61
8513812 1993
9
Lipopolysaccharide-independent radioimmunoprecipitation and identification of structural and in vivo induced immunogenic surface proteins of Salmonella typhi in typhoid fever. 54 61
8427032 1993
10
Human cell mediated immunity to porins from Salmonella typhi. 54 61
8384733 1993
11
Hyperexpression of type III secretion system of Salmonella Typhi linked to a higher cytotoxic effect to monocyte-derived macrophages by activating inflammasome. 61
32387390 2020
12
Recombinant protein production and purification of SiiD, SiiE and SiiF - Components of the SPI4-encoded type I secretion system from Salmonella Typhimurium. 61
32251835 2020
13
Laparoscopic management of gall bladder perforation secondary to typhoid-induced acalculous cholecystitis: A rare entity. 61
31793452 2020
14
Changing epidemiology of invasive non-typhoid Salmonella infection: a nationwide population-based registry study. 61
31760114 2020
15
Toxin Glycan Binding: Lectin Keys Unlocking Host and Tissue Specificity. 61
32526179 2020
16
Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies. 61
32571662 2020
17
Cardiometabolic risk in Algeria: past and present. 61
31628581 2020
18
Accessibility of O Antigens Shared between Salmonella Serovars Determines Antibody-Mediated Cross-Protection. 61
32540995 2020
19
Virulence traits and expression of bstA, fliC and sopE2 in Salmonella Dublin strains isolated from humans and animals in Brazil. 61
31931258 2020
20
Designing a typhoid environmental surveillance study: A simulation model for optimum sampling site allocation. 61
32339811 2020
21
Pre-traveller typhoid vaccinations for Australian children visiting friends and relatives overseas. A call to (inject) arms. 61
32043295 2020
22
Factors associated with occurrence of salmonellosis among children living in Mukuru slum, an urban informal settlement in Kenya. 61
32552753 2020
23
Chikungunya in Indonesia: Epidemiology and diagnostic challenges. 61
32479497 2020
24
Salmonella Typhoid Toxin PltB Subunit and Its Non-typhoidal Salmonella Ortholog Confer Differential Host Adaptation and Virulence. 61
32396840 2020
25
In vitro and in vivo anti-salmonella properties of hydroethanolic extract of Detarium microcarpum Guill. & Perr. (Leguminosae) root bark and LC-MS-based phytochemical analysis. 61
32534119 2020
26
Alexandroupolis (Dedeagatch): A city born of infections and the first documented death of the Italian civilian Giuseppe Bigheti. 61
32487795 2020
27
Typhoid Outbreaks, 1989-2018: Implications for Prevention and Control. 61
32228795 2020
28
Reviving the "Moore Swab": a Classic Environmental Surveillance Tool Involving Filtration of Flowing Surface Water and Sewage Water To Recover Typhoidal Salmonella Bacteria. 61
32332133 2020
29
Evaluation of a Rapid Point-of-Care Multiplex Immunochromatographic Assay for the Diagnosis of Enteric Fever. 61
32522777 2020
30
Case report of eventration of diaphragm due to an unknown febrile illness causing phrenic nerve palsy and other multiple nerve palsies. 61
32382413 2020
31
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. 61
31585725 2020
32
Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial. 61
32065303 2020
33
Burden of Complicated Intra-Abdominal Infections in Children in Nigeria: Recent Experience and Systematic Review. 61
32453672 2020
34
Case Report: Salmonella Enterica Serovar Paratyphi B Infection in a Febrile Ill Child during Enhanced Passive Surveillance in an Urban Slum in Mirpur, Dhaka. 61
32458786 2020
35
Estimands and inference in cluster-randomized vaccine trials. 61
32372535 2020
36
High-dose Dexamethasone in a Child With Enteric Encephalopathy Caused by Salmonella enterica serovar Typhi. 61
32176188 2020
37
Emergence of novel mutations in extensively drug resistant Salmonella Typhi from Pakistan. 61
32457111 2020
38
Francisella tularensis as the cause of protracted fever. 61
32380974 2020
39
Catastrophic Healthcare Expenditure from Typhoid Perforation in Children in Nigeria. 61
32423308 2020
40
Changes in some haematological parameters in typhoid fever patients attending Landmark University Medical Center, Omuaran-Nigeria. 61
32490233 2020
41
Epidemiologic and Epizootic Data of Tularemia in the Past and in the Recent History in Croatia. 61
32408663 2020
42
An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy. 61
32344200 2020
43
Outer membrane protein OmpV mediates Salmonella enterica serovar typhimurium adhesion to intestinal epithelial cells via fibronectin and α1β1 integrin. 61
32017350 2020
44
Underdiagnoses of Rickettsia in patients hospitalized with acute fever in Indonesia: observational study results. 61
32448167 2020
45
The YrbE phospholipid transporter of Salmonella enterica serovar Typhi regulates the expression of flagellin and influences motility, adhesion and induction of epithelial inflammatory responses. 61
31829769 2020
46
New Roles for Two-Component System Response Regulators of Salmonella enterica Serovar Typhi during Host Cell Interactions. 61
32413972 2020
47
Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq - United States, 2018-2019. 61
32437343 2020
48
Development of a Specific and Sensitive HPAEC-PAD Method for Quantification of Vi Polysaccharide Applicable to other Polysaccharides Containing Amino Uronic Acids. 61
32330386 2020
49
Morbidity and Mortality of Typhoid Intestinal Perforation Among Children in Sub-Saharan Africa 1995-2019: A Scoping Review. 61
32430740 2020
50
Salmonella Persistence and Host Immunity is Dictated by the Anatomical Microenvironment. 61
32393507 2020
Sources

Variations for Typhoid Fever

About this section
Sources

Expression for Typhoid Fever

About this section
Search GEO for disease gene expression data for Typhoid Fever.
Sources

Pathways for Typhoid Fever

About this section

Pathways related to Typhoid Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.12 TNF TLR5 TLR4 SLC11A1 LTA IL6
2
PEDF Induced Signaling 63
Show member pathways
 13.77 TNF TLR4 LTA IL6 IL1B IL1A
3
TGF-Beta Pathway 63
Show member pathways
 13.59 TNF LTA IL6 IL1B IL1A IFNGR1
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.46 TNF LTA IL6 IL1B IL1A IFNGR1
5
IL-2 Pathway 63
Show member pathways
 13.31 TNF TLR5 TLR4 IL1B IL1A IFNGR1
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.15 TNF TLR5 TLR4 IL6 IL1B IFNGR1
7
Allograft rejection 1 36
Show member pathways
 12.98 TNF LTA IL6 IL1B IL1A IFNG
8
Herpes simplex virus 1 infection 36
12.92 TNF LTA IL6 IL1B IFNGR1 IFNG
9
NF-KappaB Family Pathway 63
Show member pathways
 12.82 TNF TLR5 TLR4 LTA IL6 IL1B
10
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.82 TNF TLR5 TLR4 IL6 IL1B IL1A
11
Measles 36
Show member pathways
 12.81 VDAC1 TNF TLR4 IL6 IL1B IL1A
12
4-1BB Pathway 63
Show member pathways
 12.78 TNF LTA IL1B IL1A IFNGR1 IFNG
13
T cell receptor signaling pathway 36
Show member pathways
 12.71 TNF TLR4 IL6 IL1B IL1A IFNGR1
14
TRAF Pathway 63
Show member pathways
 12.69 TNF TLR5 TLR4 LTA IL1B IL1A
15
Immune response IL-23 signaling pathway 22
Show member pathways
 12.67 TNF IL6 IL1B IFNG F2
16
Th17 cell differentiation 36
Show member pathways
 12.62 TNF TLR5 TLR4 IL6 IL1B IL1A
17
Shigellosis 36
12.53 VDAC1 TNF TLR5 TLR4 IL1B CASP1
18
Human T-cell leukemia virus 1 infection 36
12.47 VDAC1 VAC14 TNF LTA IL6 HLA-DRB1
19
IL-17 Family Signaling Pathways 64
Show member pathways
 12.45 TNF TLR5 IL6 IL1B IFNG CFTR
20
Toll Comparative Pathway 63
Show member pathways
 12.43 TNF TLR4 IL6 IL1B IL1A IFNGR1
21
Salmonella infection (KEGG) 36
12.42 TNF TLR5 TLR4 IL6 IL1B CASP1
22
Folate Metabolism 1
Show member pathways
 12.41 TNF IL6 IL1B IFNG F2 CRP
23
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.38 TNF TLR5 TLR4 IL6 IL1A
24
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.38 TNF LTA IL6 IL1B IL1A IFNG
25
NOD-like receptor signaling pathway 36
12.35 VDAC1 TNF TLR4 IL6 IL1B CASP1
26
Pathogenic Escherichia coli infection 36
12.35 TNF TLR5 TLR4 IL6 IL1B F2
27
Toxoplasmosis 36
Show member pathways
 12.33 TNF TLR4 IL1B IL1A IFNGR1 IFNG
28
Colorectal Cancer Metastasis 63
12.3 TNF TLR5 TLR4 IL6 IFNGR1 IFNG
29
C-type lectin receptor signaling pathway 36
Show member pathways
 12.29 TNF IL6 IL1B CASP1
30
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.25 TNF IL6 IL1B IL1A
31
Tuberculosis 36
12.23 TNF TLR4 IL6 IL1B IL1A IFNGR1
32
Fluid shear stress and atherosclerosis 36
12.18 TNF IL1B IL1A IFNG
33
Osteoclast differentiation 36
12.18 TNF IL1B IL1A IFNGR1 IFNG
34
Yersinia infection 36
12.15 TNF TLR4 IL6 IL1B CASP1
35
MAPK Pathway 70
Show member pathways
 12.13 TLR5 TLR4 IL1B IL1A
36
Spinal Cord Injury 1
12.11 TNF TLR4 IL6 IL1B IL1A IFNG
37
Interleukin-4 and 13 signaling 65
12.09 TNF IL6 IL1B IL1A
38
Necroptosis 36
Show member pathways
 12.09 VDAC1 TNF TLR4 IL1B IL1A IFNGR1
39
TNF signaling pathway 36
12.08 TNF LTA IL6 IL1B
40
HIF-1 signaling pathway 36
12.07 TLR4 IL6 IFNGR1 IFNG
41
Amoebiasis 36
12.06 TNF TLR4 IL6 IL1B IFNG
42
Senescence and Autophagy in Cancer 1
12.05 IL6 IL1B IL1A IFNG
43
NF-kappa B signaling pathway 36
12.04 TNF TLR4 LTA IL1B
44
Hematopoietic cell lineage 36
12.04 TNF IL6 IL1B IL1A HLA-DRB1
45
AGE-RAGE signaling pathway in diabetic complications 36
12.02 TNF IL6 IL1B IL1A
46
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.99 IL1B IFNGR1 IFNG CASP1
47
Th17 Differentiation 64
Show member pathways
 11.98 TLR5 TLR4 IL6 IL1B IFNG
48
Bacterial infections in CF airways 22
Show member pathways
 11.98 TNF TLR5 TLR4 IL6 IL1B IFNGR1
49
Innate Lymphoid Cells Differentiation 64
11.91 TNF LTA IL1B IFNG
50
Dendritic Cells Developmental Lineage Pathway 64
11.88 TNF IL6 IL1B IFNG
Sources

GO Terms for Typhoid Fever

About this section

Cellular components related to Typhoid Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNF LTA IL6 IL1B IL1A IFNG
2 endosome membrane GO:0010008 9.35 VAC14 TLR4 SLC11A1 HLA-DRB1 CFTR

Biological processes related to Typhoid Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 VAC14 TLR5 TLR4 OMP LTA IL6
2 apoptotic process GO:0006915 10.19 VDAC1 LTA IL1B IL1A IFNG CASP1
3 cytokine-mediated signaling pathway GO:0019221 10.03 TNF IL6 IL1B IL1A IFNGR1 CASP1
4 response to lipopolysaccharide GO:0032496 10.01 TLR4 SLC11A1 LTA IL1B
5 inflammatory response GO:0006954 10.01 TNF TLR5 TLR4 SLC11A1 IL6 IL1B
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 IL6 IL1B
7 positive regulation of protein phosphorylation GO:0001934 10 TNF IL1B IFNG HLA-DRB1 F2
8 defense response to Gram-positive bacterium GO:0050830 9.97 TNF LTA IL6 CRP
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 TNF TLR4 IL1B IL1A HLA-DRB1 CASP1
10 positive regulation of inflammatory response GO:0050729 9.93 TNF TLR4 IL1B IFNG
11 cellular response to mechanical stimulus GO:0071260 9.91 TLR5 TLR4 IL1B CASP1
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 TNF IL6 IFNG
13 interferon-gamma-mediated signaling pathway GO:0060333 9.9 IFNGR1 IFNG HLA-DRB1
14 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
15 apoptotic signaling pathway GO:0097190 9.9 TNF TLR4 CASP1
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 IL1B
17 humoral immune response GO:0006959 9.88 TNF LTA IL6 IFNG
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B IL1A
19 acute-phase response GO:0006953 9.87 IL6 F2 CRP
20 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR4 IL6 IL1B
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.86 TNF TLR4 IL1B
22 positive regulation of cytokine production GO:0001819 9.86 TNF TLR5 SLC11A1
23 positive regulation of cytokine secretion GO:0050715 9.85 TNF IL1A IFNG
24 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 F2
25 microglial cell activation GO:0001774 9.85 TNF IFNGR1 IFNG
26 positive regulation of vascular endothelial growth factor production GO:0010575 9.85 IL6 IL1B IL1A
27 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
28 positive regulation of phagocytosis GO:0050766 9.83 TNF SLC11A1 IL1B IFNG
29 inflammatory response to antigenic stimulus GO:0002437 9.82 IL1B IL1A HLA-DRB1
30 positive regulation of tumor necrosis factor secretion GO:1904469 9.82 IL1A IFNGR1 IFNG
31 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.81 TNF TLR4 IL6
32 positive regulation of interleukin-8 production GO:0032757 9.81 TNF TLR5 TLR4 IL1B
33 positive regulation of amyloid-beta formation GO:1902004 9.8 TNF IFNGR1 IFNG
34 positive regulation of chemokine production GO:0032722 9.79 TNF TLR4 IL6
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 TNF IL1B IFNG
36 positive regulation of chemokine biosynthetic process GO:0045080 9.77 TNF IL1B IFNG
37 positive regulation of interferon-gamma production GO:0032729 9.77 TNF TLR4 SLC11A1 LTA IL1B
38 positive regulation of glial cell proliferation GO:0060252 9.76 TNF LTA IL6 IL1B
39 positive regulation of neuroinflammatory response GO:0150078 9.75 TNF IL6 IL1B
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IFNG
41 T-helper 1 type immune response GO:0042088 9.73 TLR4 HLA-DRB1
42 astrocyte activation GO:0048143 9.73 TNF IL1B IFNGR1 IFNG
43 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.72 TNF IFNG
44 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
45 negative regulation of amyloid-beta clearance GO:1900222 9.72 TNF IFNGR1 IFNG
46 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 TNF TLR5 TLR4 IL1B IFNG
47 ectopic germ cell programmed cell death GO:0035234 9.71 IL1B IL1A
48 interleukin-1 beta production GO:0032611 9.71 IL1B CASP1
49 positive regulation of fever generation GO:0031622 9.71 TNF IL1B
50 negative regulation of lipid storage GO:0010888 9.71 TNF IL6 CRP

Molecular functions related to Typhoid Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.13 TLR5 IL1B IL1A
2 cytokine activity GO:0005125 9.1 TNF LTA IL6 IL1B IL1A IFNG
Sources

Sources for Typhoid Fever

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....